Retinal vein occlusion (RVO) is a major cause of blindness in the major pharmaceutical markets. Patients are segmented by the anatomic location of the occlusion; thus, they are classified as having branch, central, or hemi-retinal vein occlusion (BRVO, CRVO, HRVO, respectively). Because RVOs compromise venous return from the retinal circulation, they may trigger retinal ischemia, macular edema, and/or neovascularization. The standards of care for macular edema following RVO include the anti-VEGFs Eylea (Regeneron / Bayer), Lucentis (Roche / Genentech), and off-label Avastin (Roche / Genentech) and the corticosteroid implant Ozurdex (AbbVie). Notably, Roche / Chugai expect to submit an expanded application for Vabysmo for BRVO and CRVO in the United States and Europe in 2023. Although the number of therapies in development for RVO is small, commercial opportunity remains for therapies with a longer dosing duration, greater efficacy, and/or a convenient route of administration.
3 KOL interviews in July 2023
KEY COMPANIES COVERED
Regeneron, Roche/Genentech, AbbVie (legacy Allergan), Biogen, Coherus, Annexin, 3T Ophthalmics
KEY DRUGS COVERED ANXV, Avastin, Byooviz, Cimerli, Eylea, Eylea HD, Lucentis, Ozurdex, ONS-5010 (Lytenava), RG-7921
Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.